Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa.

International Journal of DermatologyEarly View Correspondence Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa Lei Shao MD, Lei Shao MD Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, China These two authors contributed equally to this work.Search for more papers by this authorDao-qing Zhong BS, Dao-qing Zhong BS Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, China These two authors contributed equally to this work.Search for more papers by this authorYu-mei Liu MD, Corresponding Author Yu-mei Liu MD [email protected] Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, ChinaSearch for more papers by this authorJian-qin Wang MD, Corresponding Author Jian-qin Wang MD [email protected] Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, ChinaSearch for more papers by this author Lei Shao MD, Lei Shao MD Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, China These two authors contributed equally to this work.Search for more papers by this authorDao-qing Zhong BS, Dao-qing Zhong BS Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, China These two authors contributed equally to this work.Search for more papers by this authorYu-mei Liu MD, Corresponding Author Yu-mei Liu MD [email protected] Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, ChinaSearch for more papers by this authorJian-qin Wang MD, Corresponding Author Jian-qin Wang MD [email protected] Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China Institute of Dermatology, Guangzhou Medical University, Guangzhou, ChinaSearch for more papers by this author First published: 16 June 2023 https://doi.org/10.1111/ijd.16752 Conflict of interest: None. Funding sources: This study was supported by the Science and Technology General guidance project of Guangzhou Health Commission (grant number 20211A011067). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Caroppo F, Milan E, Giulioni E, Belloni Fortina A. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab. J Eur Acad Dermatol Venereol. 2022; 36: e365–7. 2Shehadeh W, Sarig O, Bar J, Sprecher E, Samuelov L. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020; 182: 1495–7. 3Wu XG, Yan S, Jiang JQ, Zhou TT, Fang X, Yang H, et al. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab. J Dermatol. 2023; 50: 837–42. 4Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017; 171: 217–228.e213. 5Zhou AG, Little AJ, Antaya RJ. Epidermolysis bullosa pruriginosa treated with dupilumab. Pediatr Dermatol. 2021; 38: 526–7. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation